Evidence-Based Data About Prevalence and Risk of Malignancy of Thyroid Incidentalomas Detected by Different PET Radiopharmaceuticals

Author(s): Giovanni Signore, Domenico Albano, Luca Giovanella, Francesco Bertagna, Giorgio Treglia*

Journal Name: Current Radiopharmaceuticals

Volume 13 , Issue 2 , 2020

Become EABM
Become Reviewer

Graphical Abstract:


Abstract:

Background: To date, several meta-analyses and systematic reviews have reported data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.

Objective: This article aims to summarize the published evidence-based data about the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals.

Methods: A comprehensive computer literature search of systematic reviews and meta-analyses published up to July 2019 in PubMed/MEDLINE and Cochrane library databases regarding the prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals was carried out.

Results: We have summarized the data about prevalence and risk of malignancy of thyroid incidentalomas detected by different PET radiopharmaceuticals (fluorine-18 fluorodeoxyglucose, radiolabelled choline and prostate-specific membrane antigen) taking into account 8 evidence-based articles.

Conclusion: Evidence-based data demonstrated that thyroid incidentalomas detected by different PET radiopharmaceuticals are not infrequent and their risk of malignancy is not negligible, in particular if focal pattern is evident at PET, thus requiring further clinical and instrumental evaluation.

Keywords: PET, thyroid, incidentaloma, prevalence, malignancy, clinical significance, radiolabelled choline, ultrasonography.

[1]
Hegedüs, L. Clinical practice. The thyroid nodule. N. Engl. J. Med., 2004, 351(17), 1764-1771.
[http://dx.doi.org/10.1056/NEJMcp031436] [PMID: 15496625]
[2]
Hegedüs, L.; Bonnema, S.J.; Bennedbaek, F.N. Management of simple nodular goiter: current status and future perspectives. Endocr. Rev., 2003, 24(1), 102-132.
[http://dx.doi.org/10.1210/er.2002-0016] [PMID: 12588812]
[3]
Paschou, S.A.; Vryonidou, A.; Goulis, D.G. Thyroid nodules: A guide to assessment, treatment and follow-up. Maturitas, 2017, 96, 1-9.
[http://dx.doi.org/10.1016/j.maturitas.2016.11.002] [PMID: 28041586]
[4]
Jin, J.; McHenry, C.R. Thyroid incidentaloma. Best Pract. Res. Clin. Endocrinol. Metab., 2012, 26(1), 83-96.
[http://dx.doi.org/10.1016/j.beem.2011.06.004] [PMID: 22305454]
[5]
Tamburello, A.; Treglia, G.; Albano, D.; Bertagna, F.; Giovanella, L. Prevalence and clinical signifi-cance of focal incidental 18F-FDG uptake in different organs: an evidence-based summary. Clin. Transl. Imaging, 2017, 5(6), 525-532.
[http://dx.doi.org/10.1007/s40336-017-0253-8]
[6]
Treglia, G.; Sadeghi, R.; Del Sole, A.; Giovanella, L. Diagnostic performance of PET/CT with tracers other than F-18-FDG in oncology: an evidence-based review. Clin. Transl. Oncol., 2014, 16(9), 770-775.
[http://dx.doi.org/10.1007/s12094-014-1168-8] [PMID: 24647843]
[7]
Sadeghi, R.; Treglia, G. Systematic reviews and meta-analyses of diagnostic studies: a practical guide-line. Clin. Transl. Imaging, 2017, 5(2), 83-87.
[http://dx.doi.org/10.1007/s40336-016-0219-2]
[8]
Treglia, G.; Sadeghi, R. Meta-analyses and systematic reviews on PET and PET/CT in oncology: the state of the art. Clin. Transl. Imaging, 2013, 1(2), 73-75.
[http://dx.doi.org/10.1007/s40336-013-0013-3]
[9]
Shie, P.; Cardarelli, R.; Sprawls, K.; Fulda, K.G.; Taur, A. Systematic review: prevalence of malignant incidental thyroid nodules identified on fluorine-18 fluorodeoxyglucose positron emission tomogra-phy. Nucl. Med. Commun., 2009, 30(9), 742-748.
[http://dx.doi.org/10.1097/MNM.0b013e32832ee09d] [PMID: 19561553]
[10]
Soelberg, K.K.; Bonnema, S.J.; Brix, T.H.; Hegedüs, L. Risk of malignancy in thyroid incidenta-lomas detected by 18F-fluorodeoxyglucose positron emission tomography: a systematic review. Thyroid, 2012, 22(9), 918-925.
[http://dx.doi.org/10.1089/thy.2012.0005] [PMID: 22827552]
[11]
Bertagna, F.; Treglia, G.; Piccardo, A.; Giubbini, R. Diagnostic and clinical significance of F-18-FDG-PET/CT thyroid incidentalomas. J. Clin. Endocrinol. Metab., 2012, 97(11), 3866-3875.
[http://dx.doi.org/10.1210/jc.2012-2390] [PMID: 22904176]
[12]
Treglia, G.; Bertagna, F.; Sadeghi, R.; Verburg, F.A.; Ceriani, L.; Giovanella, L. Focal thyroid in-cidental uptake detected by 18F-fluorodeoxyglucose positron emission tomography. Nucl. Med. (Stuttg.), 2013, 52(4), 130-136.
[http://dx.doi.org/10.3413/Nukmed-0568-13-03] [PMID: 23765102]
[13]
Nayan, S.; Ramakrishna, J.; Gupta, M.K. The proportion of malignancy in incidental thyroid le-sions on 18-FDG PET study: a systematic review and meta-analysis. Otolaryngol. Head Neck Surg., 2014, 151(2), 190-200.
[http://dx.doi.org/10.1177/0194599814530861] [PMID: 24759908]
[14]
Qu, N.; Zhang, L.; Lu, Z.W.; Wei, W.J.; Zhang, Y.; Ji, Q.H. Risk of malignancy in focal thyroid lesions identified by (18)F-fluorodeoxyglucose positron emission tomography or positron emission tomography/computed tomography: evidence from a large series of studies. Tumour Biol., 2014, 35(6), 6139-6147.
[http://dx.doi.org/10.1007/s13277-014-1813-4] [PMID: 24622887]
[15]
Bertagna, F.; Albano, D.; Giovanella, L.; Giubbini, R.; Treglia, G. F18-choline/C11-choline PET/CT thyroid incidentalomas. Endocrine, 2019, 64(2), 203-208.
[http://dx.doi.org/10.1007/s12020-019-01841-z] [PMID: 30637562]
[16]
Bertagna, F.; Albano, D.; Giovanella, L.; Bonacina, M.; Durmo, R.; Giubbini, R.; Treglia, G. 68Ga-PSMA PET thyroid incidentalomas. Hormones (Athens), 2019, 18(2), 145-149.
[http://dx.doi.org/10.1007/s42000-019-00106-8] [PMID: 30989578]
[17]
Treglia, G.; Pereira Mestre, R.; Ferrari, M.; Bosetti, D.G.; Pascale, M.; Oikonomou, E.; De Dosso, S.; Jermini, F.; Prior, J.O.; Roggero, E.; Giovanella, L. Radiolabelled choline versus PSMA PET/CT in prostate cancer restaging: a meta-analysis. Am. J. Nucl. Med. Mol. Imaging, 2019, 9(2), 127-139.
[PMID: 31139496]
[18]
Nockel, P.; Millo, C.; Keutgen, X.; Klubo-Gwiezdzinska, J.; Shell, J.; Patel, D.; Nilubol, N.; Her-scovitch, P.; Sadowski, S.M.; Kebebew, E. The rate and clinical significance of incidental thyroid up-take as detected by gallium-68 DOTATATE positron emission tomography/computed tomography. Thyroid, 2016, 26(6), 831-835.
[http://dx.doi.org/10.1089/thy.2016.0174] [PMID: 27094616]
[19]
Kunikowska, J.; Matyskiel, R.; Zemczak, A.; Strzelczyk, J.; Pawlak, D.; Królicki, L.; Kos-Kudła, B. How often do we see incidental 68Ga-DOTATATE thyroid uptake in PET/CT in patients with neu-roendocrine tumours? Endokrynol. Pol., 2015, 66(3), 231-236.
[http://dx.doi.org/10.5603/EP.2015.0030] [PMID: 26136132]
[20]
Sollini, M.; Cozzi, L.; Pepe, G.; Antunovic, L.; Lania, A.; Di Tommaso, L.; Magnoni, P.; Erba, P.A.; Kirienko, M. [18F]FDG-PET/CT texture analysis in thyroid incidentalomas: preliminary results. Eur J Hybrid Imaging, 2017, 1(1), 3.
[http://dx.doi.org/10.1186/s41824-017-0009-8] [PMID: 29782578]
[21]
Pattison, D.A.; Bozin, M.; Gorelik, A.; Hofman, M.S.; Hicks, R.J.; Skandarajah, A. 18F-FDG-Avid thyroid incidentalomas: the importance of contextual interpretation. J. Nucl. Med., 2018, 59(5), 749-755.
[http://dx.doi.org/10.2967/jnumed.117.198085] [PMID: 29025986]


Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 13
ISSUE: 2
Year: 2020
Published on: 03 August, 2020
Page: [89 - 93]
Pages: 5
DOI: 10.2174/1874471012666191212115732
Price: $65

Article Metrics

PDF: 13
HTML: 2
EPUB: 2
PRC: 1